Alopecia Totalis Clinical Trial
Official title:
Safety and Efficacy of Oral Mega Pulse Methylprednisolone in Severe Therapy Resistant Alopecia Areata
Systemic Pulse Glucocorticoids have been shown to be effective in widespread Alopecia areata but not the totalis, universalis or ophiasic type. Whether the failure is due to inadequate dosing, inadequate frequency or other factors is a matter of debate. The investigators decided to conduct this study using the oral pulse steroid, however with higher doses and more frequent pulses to patients with severe forms of Alopecia areata.
This will be a single-center, prospective, randomized study conducted in King Khalid University Hospital. Patients diagnosed with either Alopecia universalis, Alopecia totalis or Ophiasic alopecia will be included in the study. Patients with contraindications such as diabetes mellitus, peptic ulcer, hypertension, infection, psychosis, heart or kidney disease, endocrine disorders (apart from a subclinical hypothyroidism and autoimmune thyroiditis) will be excluded. Children less than 5 years of age and those who received systemic or topical treatment within the last 4 weeks before enrollment will be also excluded. Those of child bearing potential had to have a negative urine pregnancy test result at baseline visit and should practice a reliable method of contraception throughout the study. 42 eligible patients will be randomly assigned to one of 3 treatment groups. Enrolled patients must provide written informed consent. Institutional review board approval will be obtained. ;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02812342 -
Topical Tofacitinib for the Treatment of Alopecia Areata and Its Variants
|
Phase 2 | |
Recruiting |
NCT04011748 -
Clinical Application of Stem Cell Educator Therapy in Alopecia Areata
|
Phase 2 | |
Withdrawn |
NCT03532958 -
Phase 2 Trial of BNZ-1 in Patients With Moderate to Severe Alopecia Areata
|
Phase 2 | |
Completed |
NCT05098600 -
The Epidemiology, Management and Comorbidities in Alopecia Areata in Czech Republic
|
||
Active, not recruiting |
NCT00069589 -
Alopecia Areata Registry
|
||
Completed |
NCT06278402 -
Efficacy of Oral Tofacitinib in Moderate to Severe Alopecia Areata, Totalis and Universalis at Tertiary Care Hospital, Karachi.
|
Phase 3 | |
Recruiting |
NCT06283316 -
Systemic Treatments for Alopecia Areata Registry
|
||
Terminated |
NCT03759340 -
ATI-502 Topical Solution for the Treatment of Alopecia Areata (AA), Alopecia Universalis (AU) and Alopecia Totalis (AT)
|
Phase 2 | |
Completed |
NCT02312882 -
Tofacitinib for the Treatment of Alopecia Areata and Its Variants
|
N/A | |
Completed |
NCT05589610 -
Study of EQ101 in Adult Subjects With Moderate to Severe Alopecia Areata
|
Phase 2 | |
Withdrawn |
NCT04238091 -
Clinical Trial to Evaluate the Efficacy of Fecal Microbiota Transplantation in Patients With Alopecia Areata
|
Phase 2 | |
Withdrawn |
NCT00746980 -
Efalizumab in the Treatment of Alopecia, Phase II
|
Phase 2 | |
Completed |
NCT03551821 -
Open Label Study of ATI-50002 Topical Solution Administered to Adult Subjects With Eyebrow Loss Due to Alopecia Areata
|
Phase 2 |